TDMS Study 96007-04 Pathology Tables
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
FINAL#4/RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFDIOXINMIX
Lock Date: 09/12/01
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 98 98 98 98
Early Deaths
Moribund Sacrifice 26 25 22 25 33
Natural Death 11 5 6 4 10
Dosing Accident 1 1 2
Survivors
Terminal Sacrifice 16 23 24 23 8
Animals Examined Microscopically 53 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (53) (53) (53) (53)
Muscularis, Inflammation 2 (4%) 1 (2%) 1 (2%)
Intestine Large, Colon (53) (52) (53) (53) (51)
Parasite Metazoan 1 (2%)
Intestine Large, Rectum (52) (53) (53) (53) (52)
Parasite Metazoan 2 (4%) 4 (8%) 5 (9%) 1 (2%)
Artery, Inflammation, Chronic Active 2 (4%) 3 (6%)
Serosa, Inflammation 1 (2%)
Intestine Large, Cecum (51) (53) (53) (53) (51)
Artery, Inflammation, Chronic Active 1 (2%)
Intestine Small, Duodenum (52) (53) (53) (53) (52)
Serosa, Inflammation, Chronic Active 1 (2%)
Liver (53) (53) (53) (53) (51)
Angiectasis 3 (6%) 2 (4%) 3 (6%)
Basophilic Focus 9 (17%) 14 (26%) 10 (19%) 5 (9%) 8 (16%)
Basophilic Focus, Multiple 15 (28%) 12 (23%) 3 (6%) 7 (13%) 8 (16%)
Cholangiofibrosis 2 (4%) 3 (6%) 4 (8%) 17 (33%)
Clear Cell Focus 1 (2%) 1 (2%)
Clear Cell Focus, Multiple 1 (2%) 1 (2%)
Degeneration, Cystic 1 (2%) 1 (2%) 2 (4%)
Eosinophilic Focus 4 (8%) 2 (4%) 5 (9%) 5 (9%)
Eosinophilic Focus, Multiple 1 (2%) 7 (13%) 6 (11%) 15 (28%) 19 (37%)
Fatty Change, Diffuse 3 (6%) 5 (9%) 14 (26%) 34 (64%) 36 (71%)
Fatty Change, Focal 3 (6%) 4 (8%) 7 (13%) 2 (4%) 1 (2%)
Hematopoietic Cell Proliferation 16 (30%) 18 (34%) 19 (36%) 8 (15%) 9 (18%)
Hepatodiaphragmatic Nodule 1 (2%)
Hyperplasia, Nodular 1 (2%) 3 (6%) 11 (21%) 38 (75%)
Inflammation 36 (68%) 50 (94%) 45 (85%) 50 (94%) 50 (98%)
Karyomegaly 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Mixed Cell Focus 4 (8%) 5 (9%) 5 (9%) 1 (2%)
Mixed Cell Focus, Multiple 17 (32%) 27 (51%) 30 (57%) 35 (66%) 17 (33%)
Necrosis 3 (6%) 1 (2%) 9 (17%) 3 (6%) 15 (29%)
Pigmentation 4 (8%) 35 (66%) 41 (77%) 48 (91%) 51 (100%)
Toxic Hepatopathy 5 (9%) 14 (26%) 38 (72%) 47 (92%)
Bile Duct, Cyst 1 (2%) 3 (6%) 3 (6%) 4 (8%) 9 (18%)
Bile Duct, Dilatation 1 (2%) 1 (2%)
Bile Duct, Fibrosis 3 (6%) 2 (4%) 1 (2%) 5 (9%) 1 (2%)
Bile Duct, Hyperplasia 2 (4%) 3 (6%) 5 (9%) 25 (47%) 42 (82%)
Centrilobular, Degeneration 3 (6%) 2 (4%) 1 (2%) 1 (2%) 6 (12%)
Centrilobular, Fibrosis 1 (2%)
Hepatocyte, Hypertrophy 1 (2%) 27 (51%) 34 (64%) 46 (87%) 50 (98%)
Hepatocyte, Multinucleated 12 (23%) 10 (19%) 39 (74%) 51 (100%)
Oval Cell, Hyperplasia 1 (2%) 1 (2%) 26 (49%) 42 (82%)
Portal, Fibrosis 11 (22%)
Serosa, Fibrosis 1 (2%)
Serosa, Inflammation, Chronic 1 (2%)
Mesentery (1) (2) (6) (8)
Inflammation, Chronic Active 2 (25%)
Necrosis 1 (50%) 1 (13%)
Artery, Inflammation, Chronic Active 1 (100%) 3 (50%) 6 (75%)
Fat, Necrosis 1 (50%) 2 (33%)
Oral Mucosa (10) (18) (19) (29) (31)
Gingival, Hyperplasia, Squamous 8 (80%) 17 (94%) 18 (95%) 26 (90%) 30 (97%)
Pancreas (52) (53) (53) (53) (51)
Degeneration 1 (2%)
Inflammation, Chronic Active 3 (6%) 1 (2%) 6 (11%) 7 (13%) 16 (31%)
Inflammation, Granulomatous 1 (2%)
Acinus, Atrophy 3 (6%) 2 (4%) 7 (13%) 7 (13%) 20 (39%)
Acinus, Hyperplasia 2 (4%) 1 (2%)
Acinus, Vacuolization Cytoplasmic 1 (2%) 3 (6%) 15 (28%) 30 (59%)
Artery, Inflammation, Chronic Active 6 (11%) 3 (6%) 8 (15%) 14 (27%)
Duct, Cyst 1 (2%)
Duct, Dilatation 5 (10%)
Duct, Inflammation, Chronic Active 2 (4%)
Salivary Glands (53) (53) (53) (53) (53)
Atrophy 1 (2%)
Inflammation 2 (4%) 1 (2%)
Mineralization 1 (2%)
Stomach, Forestomach (53) (53) (53) (53) (52)
Cyst 1 (2%) 1 (2%)
Diverticulum 1 (2%)
Edema 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Erosion 1 (2%)
Hyperkeratosis 2 (4%) 2 (4%)
Hyperplasia, Squamous 5 (9%) 1 (2%) 4 (8%) 9 (17%) 6 (12%)
Inflammation 2 (4%) 2 (4%) 1 (2%) 3 (6%)
Mineralization 1 (2%) 4 (8%) 2 (4%)
Ulcer 3 (6%) 2 (4%) 1 (2%) 2 (4%)
Artery, Inflammation, Chronic Active 2 (4%) 1 (2%)
Stomach, Glandular (53) (53) (53) (53) (52)
Erosion 1 (2%)
Mineralization 2 (4%) 4 (8%) 3 (6%) 3 (6%) 1 (2%)
Artery, Inflammation, Chronic Active 2 (4%)
Tongue (1) (1)
Infiltration Cellular 1 (100%)
Tooth (24) (23) (27) (37) (30)
Peridontal Tissue, Inflammation 23 (96%) 21 (91%) 22 (81%) 34 (92%) 30 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (53) (53) (52) (53)
Aorta, Mineralization 1 (2%) 3 (6%)
Heart (53) (53) (53) (52) (53)
Cardiomyopathy 11 (21%) 26 (49%) 31 (58%) 30 (58%) 32 (60%)
Inflammation, Suppurative 1 (2%) 1 (2%)
Mineralization 1 (2%)
Necrosis 1 (2%)
Thrombosis 1 (2%) 1 (2%)
Artery, Degeneration 1 (2%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (52) (53) (53) (53) (51)
Angiectasis 15 (29%) 20 (38%) 18 (34%) 17 (32%) 8 (16%)
Atrophy 3 (6%) 18 (35%)
Degeneration, Cystic 9 (17%) 15 (28%) 19 (36%) 25 (47%) 16 (31%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hyperplasia 12 (23%) 26 (49%) 23 (43%) 25 (47%) 21 (41%)
Hypertrophy 44 (85%) 45 (85%) 47 (89%) 46 (87%) 45 (88%)
Inflammation 1 (2%)
Mineralization 1 (2%) 1 (2%)
Necrosis 2 (4%) 2 (4%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Thrombosis 1 (2%)
Vacuolization Cytoplasmic 6 (12%) 13 (25%) 11 (21%) 7 (13%) 15 (29%)
Capsule, Inflammation 1 (2%) 1 (2%)
Adrenal Medulla (52) (53) (53) (53) (51)
Hyperplasia 10 (19%) 21 (40%) 12 (23%) 15 (28%) 9 (18%)
Islets, Pancreatic (52) (53) (53) (53) (51)
Hyperplasia 1 (2%) 2 (4%)
Pituitary Gland (53) (53) (53) (53) (53)
Angiectasis 6 (11%) 1 (2%) 2 (4%) 3 (6%)
Cyst 1 (2%) 1 (2%) 2 (4%)
Cytoplasmic Alteration 3 (6%)
Hemorrhage 1 (2%)
Vacuolization Cytoplasmic 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Pars Distalis, Hyperplasia 18 (34%) 19 (36%) 24 (45%) 20 (38%) 19 (36%)
Pars Intermedia, Cyst 1 (2%)
Thyroid Gland (53) (53) (51) (52) (51)
C-Cell, Hyperplasia 24 (45%) 24 (45%) 20 (39%) 18 (35%) 14 (27%)
Follicular Cell, Hyperplasia 1 (2%)
Follicular Cell, Hypertrophy 4 (8%) 13 (25%) 12 (24%) 18 (35%) 23 (45%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (51) (53) (53) (51) (50)
Hyperplasia, Squamous 1 (2%)
Inflammation 42 (82%) 40 (75%) 37 (70%) 33 (65%) 29 (58%)
Duct, Cyst 39 (76%) 41 (77%) 44 (83%) 39 (76%) 44 (88%)
Ovary (52) (52) (53) (53) (51)
Atrophy 44 (85%) 44 (85%) 43 (81%) 49 (92%) 40 (78%)
Cyst 8 (15%) 16 (31%) 20 (38%) 14 (26%) 7 (14%)
Fibrosis 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 2 (4%) 5 (10%)
Artery, Inflammation, Chronic Active 1 (2%)
Oviduct (2) (2) (5)
Cyst 2 (100%) 1 (20%)
Inflammation, Chronic Active 2 (100%) 4 (80%)
Uterus (52) (53) (53) (53) (51)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Adenomyosis 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%) 1 (2%) 3 (6%)
Inflammation, Suppurative 6 (12%) 5 (9%) 9 (17%) 13 (25%) 6 (12%)
Metaplasia, Squamous 21 (40%) 32 (60%) 32 (60%) 35 (66%) 30 (59%)
Necrosis 1 (2%)
Thrombosis 1 (2%)
Ulcer 1 (2%) 1 (2%)
Cervix, Hyperplasia, Stromal 1 (2%)
Endometrium, Fibrosis 1 (2%)
Endometrium, Hyperplasia, Cystic 37 (71%) 35 (66%) 34 (64%) 33 (62%) 23 (45%)
Epithelium, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (53) (53) (53) (53)
Hyperplasia 36 (68%) 36 (68%) 34 (64%) 41 (77%) 48 (91%)
Lymph Node (4) (1) (2) (9) (11)
Lumbar, Ectasia 1 (50%)
Lumbar, Hemorrhage 1 (50%)
Lumbar, Hyperplasia, Lymphoid 1 (50%) 1 (9%)
Lumbar, Hyperplasia, Plasma Cell 1 (25%) 3 (33%)
Mediastinal, Ectasia 1 (100%) 4 (44%) 2 (18%)
Mediastinal, Fibrosis 1 (11%)
Mediastinal, Hemorrhage 1 (11%) 2 (18%)
Mediastinal, Hyperplasia, Histiocytic 1 (11%) 1 (9%)
Mediastinal, Hyperplasia, Lymphoid 2 (18%)
Mediastinal, Hyperplasia, Plasma Cell 3 (27%)
Pancreatic, Ectasia 1 (25%)
Pancreatic, Hyperplasia 1 (9%)
Pancreatic, Hyperplasia, Histiocytic 1 (9%)
Popliteal, Hyperplasia, Plasma Cell 1 (11%)
Renal, Hyperplasia, Histiocytic 1 (25%)
Lymph Node, Mandibular (53) (53) (53) (53) (53)
Ectasia 1 (2%) 1 (2%) 2 (4%)
Hemorrhage 1 (2%)
Hyperplasia, Plasma Cell 31 (58%) 42 (79%) 30 (57%) 22 (42%) 27 (51%)
Necrosis, Focal 1 (2%)
Lymph Node, Mesenteric (52) (53) (53) (53) (50)
Ectasia 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia, Histiocytic 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Pigmentation 1 (2%)
Spleen (52) (53) (53) (53) (51)
Hematopoietic Cell Proliferation 43 (83%) 48 (91%) 42 (79%) 44 (83%) 42 (82%)
Hemorrhage 1 (2%)
Inflammation, Suppurative 1 (2%)
Necrosis 1 (2%) 1 (2%)
Pigmentation 45 (87%) 50 (94%) 52 (98%) 47 (89%) 46 (90%)
Lymphoid Follicle, Atrophy 1 (2%) 2 (4%) 3 (6%) 2 (4%) 3 (6%)
Red Pulp, Atrophy 1 (2%) 3 (6%)
Thymus (52) (48) (50) (53) (50)
Atrophy 32 (62%) 43 (90%) 45 (90%) 50 (94%) 48 (96%)
Cyst 2 (4%)
Ectopic Thyroid 1 (2%)
Hemorrhage 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (53) (53) (53) (52)
Cyst 3 (6%) 1 (2%) 1 (2%)
Hyperplasia 22 (42%) 7 (13%) 14 (26%) 12 (23%) 9 (17%)
Inflammation, Granulomatous 3 (6%) 4 (8%) 1 (2%) 3 (6%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Skin (53) (53) (53) (53) (53)
Cyst Epithelial Inclusion 2 (4%) 1 (2%) 3 (6%) 3 (6%)
Hyperkeratosis 1 (2%)
Inflammation, Suppurative 1 (2%)
Ulcer 1 (2%) 1 (2%)
Hair Follicle, Atrophy 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (53) (53) (53) (53) (53)
Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (53) (53) (53) (53)
Edema 1 (2%) 3 (6%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM - CONT
Gliosis 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hydrocephalus 1 (2%) 4 (8%) 2 (4%) 2 (4%)
Inflammation, Granulomatous 1 (2%)
Mineralization 1 (2%) 1 (2%) 1 (2%)
Necrosis 3 (6%)
Artery, Degeneration 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (53) (53) (53) (53)
Congestion 1 (2%) 1 (2%)
Cyst 1 (2%)
Edema 2 (4%) 2 (4%) 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Infiltration Cellular, Histiocyte 43 (81%) 50 (94%) 48 (91%) 48 (91%) 50 (94%)
Inflammation 4 (8%) 2 (4%) 3 (6%) 1 (2%) 2 (4%)
Metaplasia, Squamous 2 (4%) 2 (4%) 8 (15%) 11 (21%)
Mineralization 1 (2%)
Alveolar Epithelium, Hyperplasia 21 (40%) 25 (47%) 10 (19%) 2 (4%) 2 (4%)
Alveolar Epithelium, Metaplasia, Bronchiolar 20 (38%) 33 (62%) 41 (77%) 40 (75%)
Perivascular, Inflammation, Chronic Active 1 (2%)
Nose (53) (53) (53) (53) (53)
Inflammation 1 (2%) 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Goblet Cell, Hyperplasia 2 (4%) 1 (2%)
Goblet Cell, Septum, Hyperplasia 1 (2%)
Nasolacrimal Duct, Inflammation 1 (2%)
Respiratory Epithelium, Hyperplasia 1 (2%) 4 (8%)
Turbinate, Cyst 1 (2%)
Turbinate, Respiratory Epithelium,
Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (53) (53) (53) (53)
Anterior Chamber, Ciliary Body, Iris,
Inflammation, Suppurative 1 (2%)
Cornea, Inflammation, Suppurative 1 (2%)
Lens, Degeneration 1 (2%)
Retina, Atrophy 1 (2%) 1 (2%) 2 (4%) 1 (2%) 3 (6%)
Harderian Gland (53) (53) (52) (53) (53)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:19
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - CONT
Inflammation 8 (15%) 11 (21%) 4 (8%) 5 (9%) 7 (13%)
Inflammation, Chronic Active 1 (2%)
Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (52) (53) (53) (53) (51)
Calculus Micro Observation Only 9 (17%) 5 (9%) 8 (15%) 4 (8%) 1 (2%)
Casts Protein 1 (2%) 1 (2%)
Cyst 1 (2%) 1 (2%)
Developmental Malformation 1 (2%)
Fibrosis 1 (2%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Inflammation, Suppurative 3 (6%) 2 (4%) 3 (6%) 3 (6%) 6 (12%)
Mineralization 41 (79%) 48 (91%) 47 (89%) 42 (79%) 35 (69%)
Nephropathy 26 (50%) 41 (77%) 40 (75%) 47 (89%) 49 (96%)
Pelvis, Dilatation 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Pelvis, Inflammation 2 (4%) 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Renal Tubule, Hyperplasia 2 (4%)
Renal Tubule, Necrosis 1 (2%) 1 (2%)
Transitional Epithelium, Hyperplasia 5 (10%) 5 (9%) 8 (15%) 10 (19%) 8 (16%)
Ureter (1) (1) (1) (1)
Cyst 1 (100%)
Inflammation 1 (100%)
Metaplasia, Squamous 1 (100%)
Transitional Epithelium, Hyperplasia 1 (100%) 1 (100%)
Urinary Bladder (52) (52) (53) (53) (50)
Edema 1 (2%)
Hemorrhage 1 (2%)
Inflammation 12 (23%) 3 (6%) 4 (8%) 8 (15%) 5 (10%)
Metaplasia, Squamous 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%) 3 (6%) 4 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------